News
BMRN
57.18
+2.05%
1.15
How Investors Are Reacting To BioMarin (BMRN) Lowered Revenue Guidance
Simply Wall St · 3d ago
Four undervalued healthcare stocks with the highest year-over-year CapEx growth
Seeking Alpha · 4d ago
BioMarin Pharmaceutical Price Target Cut to $86.00/Share From $87.00 by JP Morgan
Dow Jones · 5d ago
BioMarin Pharmaceutical Is Maintained at Overweight by JP Morgan
Dow Jones · 5d ago
JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86
Benzinga · 5d ago
BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
Seeking Alpha · 5d ago
BioMarin to Participate in Upcoming Investor Conferences
PR Newswire · 5d ago
BioMarin price target lowered to $86 from $87 at JPMorgan
TipRanks · 5d ago
BioMarin Pharmaceutical (BMRN) Stock Dropped, What Is Behind Its Latest Update?
Simply Wall St · 5d ago
Analysts Offer Insights on Healthcare Companies: Amplia Therapeutics (OtherINNMF), Pfizer (PFE) and BioMarin Pharmaceutical (BMRN)
TipRanks · 6d ago
BioMarin Pharmaceutical Price Target Cut to $119.00/Share From $122.00 by Morgan Stanley
Dow Jones · 6d ago
BioMarin Pharmaceutical Is Maintained at Overweight by Morgan Stanley
Dow Jones · 6d ago
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119
Benzinga · 6d ago
BioMarin Pharmaceutical Is Maintained at Outperform by Oppenheimer
Dow Jones · 6d ago
BioMarin Pharmaceutical Price Target Cut to $94.00/Share From $97.00 by Oppenheimer
Dow Jones · 6d ago
BioMarin Pharmaceutical Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94
Benzinga · 6d ago
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target
Benzinga · 6d ago
BioMarin Pharmaceutical Is Maintained at Sector Perform by RBC Capital
Dow Jones · 6d ago
BioMarin Pharmaceutical Price Target Cut to $60.00/Share From $62.00 by RBC Capital
Dow Jones · 6d ago
More
Webull provides a variety of real-time BMRN stock news. You can receive the latest news about Biomarin Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene.